



Corporate Fact Sheet

October 2009

ABOUT SUNEVA MEDICAL, INC.™

Suneva Medical, Inc. is a privately-held medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company was formed in April 2009 and is backed by Cowen Healthcare Royalty Partners, L.P., a global healthcare private equity firm, with \$500 million in capital under management.

Artefill® is Suneva Medical's first product and the Company legally owns and distributes Artefill in the U.S. The Company possesses a proprietary platform technology based on formulations of microsphere-enhanced collagen. Artefill is the first product to be developed using this technology but the platform has broad therapeutic applicability in the dermatology, plastic and cosmetic surgery markets including acne or traumatic scars and non-surgical rhinoplasty. Suneva Medical's strong intellectual property portfolio is well protected with several U.S. and international patents.

PRODUCT PORTFOLIO

Artefill was approved by the U.S. Food and Drug Administration in October 2006 and is the first and only microsphere-enhanced collagen filler for the correction of nasolabial folds, or smile lines. Unlike temporary muscle paralytics and other dermal fillers which are comprised of materials that are readily metabolized and absorbed by the body, Artefill uses a proprietary combination of microspheres and collagen to deliver a long lasting solution for patients. The microspheres contained in Artefill provide a support structure to fill in existing wrinkles and provide lasting wrinkle correction.

Since its commercial launch in February 2007, Artefill has gained acceptance among physicians and patients who want a safe, long lasting solution to eliminate wrinkles. The product's efficacy and safety profile has been validated through many clinical studies pre- and post-FDA approval and since its introduction to the U.S. market, over 15,000 patients have been treated with Artefill.

A prospective five-year study of 1,000 patients is currently being conducted to evaluate the long term safety of Artefill.

MANAGEMENT TEAM

Niv E. Caviar

President and Chief Executive Officer

Karon J. Morrell

Senior Vice President, Regulatory and Quality Affairs

Marcus C. Webb

Vice President Manufacturing and Engineering

Joseph Z. Rudman

Vice President, Sales

Larry Milocco

Sr. Director, Marketing

Lisa Misell, Ph.D.

Director, Medical Affairs and Clinical Operations

AT-A-GLANCE

- Status: Privately-held
- Founded: April 2009
- Products: Artefill U.S. FDA approved October 2006
- Headquarters: San Diego, CA
- Key Investors: Cowen Healthcare Royalty Partners

Suneva Medical, Inc.

5870 Pacific Center Blvd.

San Diego, CA 92121

858.550.9999

info@sunevamedical.com

www.sunevamedical.com or www.artefill.com